A Phase I Trial of Imatinib Mesylate, Bevacizumab, and Metronomic Cyclophosphamide as Antiangiogenic Therapy in Refractory Metastatic Solid Tumors.

Trial Profile

A Phase I Trial of Imatinib Mesylate, Bevacizumab, and Metronomic Cyclophosphamide as Antiangiogenic Therapy in Refractory Metastatic Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2012

At a glance

  • Drugs Bevacizumab; Cyclophosphamide; Imatinib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Apr 2012 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
    • 03 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Feb 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top